Section one: Contracting authority
one.1) Name and addresses
Newcastle University
Newcastle University, Procurement Services, Kingsgate
Newcastle
NE1 7RU
Contact
Mrs Natalie Morton
Telephone
+44 1912086396
Country
United Kingdom
Region code
UKC - North East (England)
Internet address(es)
Main address
Buyer's address
one.1) Name and addresses
Durham University
The Palatine Centre, Stockton Road
Country
United Kingdom
Region code
UKC - North East (England)
Internet address(es)
Main address
one.1) Name and addresses
Northumbria University Newcastle Newcastle
Newcastle upon Tyne
Country
United Kingdom
Region code
UKC - North East (England)
Internet address(es)
Main address
one.1) Name and addresses
University of Sunderland
Sunderland
Cheryl.Holmstrom@sunderland.ac.uk
Country
United Kingdom
Region code
UKC - North East (England)
Internet address(es)
Main address
one.1) Name and addresses
Teesside University
Middlesbrough, Tees Valley
Country
United Kingdom
Region code
UKC - North East (England)
Internet address(es)
Main address
one.1) Name and addresses
University of Bath on behalf of the SETsquared
Claverton Down, Bath
Country
United Kingdom
Region code
UK - United Kingdom
Internet address(es)
Main address
one.2) Information about joint procurement
The contract involves joint procurement
The contract is awarded by a central purchasing body
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Education
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.
Reference number
DN621813
two.1.2) Main CPV code
- 79400000 - Business and management consultancy and related services
two.1.3) Type of contract
Services
two.1.4) Short description
Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.
The initial brief of the executive will be to:
Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;
Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board
Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;
b. Work with the Unit TT team to obtain founder academics’ and University approval for appointment as CEO.
c. Provide to the University of Bath all matters necessary for Research England reporting requirements.
Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding
Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £30,000
two.2) Description
two.2.3) Place of performance
NUTS codes
- UKC - North East (England)
two.2.4) Description of the procurement
Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively.
The initial brief of the executive will be to:
Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck;
Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board
Phase (3) January 2023-March 2023 – a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University;
b. Work with the Unit TT team to obtain founder academics’ and University approval for appointment as CEO.
c. Provide to the University of Bath all matters necessary for Research England reporting requirements.
Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding
Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.
two.2.5) Award criteria
Quality criterion - Name: Ability to meet the required job description / Weighting: Pass/Fail
Quality criterion - Name: Quality: Ability to meet the Job Description / Weighting: Pass/Fail and 60%
Quality criterion - Name: Equity / Weighting: Pass/Fail
Price - Weighting: 40
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: Yes
Identification of the project
Northern Accelerator programme involving funding from both the European Regional Development Funding (ERDF) and Research England
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Restricted procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the setting up of a dynamic purchasing system
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2022/S 186-528050
Section five. Award of contract
Contract No
(NU/1433-37)
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
21 September 2022
five.2.2) Information about tenders
Number of tenders received: 3
Number of tenders received from SMEs: 3
Number of tenders received from tenderers from other EU Member States: 0
Number of tenders received from tenderers from non-EU Member States: 3
Number of tenders received by electronic means: 3
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Cambridge Drug Discovery
35 Tunwells Lane, Great Shelford,
Cambridgeshire
CB22 5LJ
Country
United Kingdom
NUTS code
- UKC - North East (England)
The contractor is an SME
Yes
five.2.4) Information on value of contract/lot (excluding VAT)
Total value of the contract/lot: £30,000
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
Newcastle University
Tyne and Wear
NE1 7RU
Country
United Kingdom
six.4.2) Body responsible for mediation procedures
Newcastle University
Tyne and Wear
Country
United Kingdom
six.4.3) Review procedure
Precise information on deadline(s) for review procedures
The University will incorporate a standstill period at the point information on the award of the
contract is communicated to tenderers. That notification will provide full information on the
award decision. The standstill period, which will be for a minimum of 10 calendar days,
provides time for unsuccessful tenderers to challenge the award decision before the
contract is entered into.
The Public Contracts Regulations 2015 (SI 2015 No 102) provide for aggrieved parties who
have been harmed or are at risk of harm by a breach of the rules to take action in the High
Court (England, Wales and Northern Ireland) within 30 days of knowledge or constructive
knowledge of breach.
six.4.4) Service from which information about the review procedure may be obtained
Newcastle University
Tyne and Wear
Country
United Kingdom